Safety review of adult clinical trial experience with lamotrigine

Drug Safety

Volumn 18, Issue 4, 1998, Pages 281-296

  Messenheimer, John ^a   Mullens, E Lynette ^b   Giorgi, Luigi ^b   Young, Frances ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG SAFETY; EPILEPSY; HUMAN; META ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; RISK FACTOR; SCHOOL CHILD; STEVENS JOHNSON SYNDROME;

ADOLESCENT; ADULT; ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; EXANTHEMA; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; RISK FACTORS; SEIZURES; TRIAZINES;

EID: 0031955433     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199818040-00004     Document Type: Article

References (28)

1. Leach MJ, Lees G, Riddall DR. Lamotrigine: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 861-9
2. +channels in rat hippocampal neurones. Pflugers Arch-Eur J Physiol 1995; 430: 437-6
3. Hosford DA, Wang Y, Utility of lethargic (Ih/Ih) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1991 Apr; 38 (4): 408-14
4. Motte J, Trevathan E, Arvidsson JFV, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut Syndrome. N Engl J Med 1997; 337 (25): 1807-12
5. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996; 5: 149-31
6. Uvebrant P, Bauzienne R. Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure related benefits. Neuropediatrics 1994; 25: 284-9
7. Sander JWAS, Trevisol-Bittencourt PC, Hart YM, et al. The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilep Res 1990 Dec; 7: 226-9
8. Krejcova H, Salemanova Z, Tmavska Z, et al. The efficacy and long-term tolerability of lamotrigine in the treatment-resistant epilepsy [abstract]. J Neurol 1990; 237 Suppl 1: S32
9. Binnie CD, Debets RMC, Engelsman M, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilep Res 1989 Nov-Dec; 4: 222-9
10. Loisiau P, Yuen AWC, Duche B, et al. A randomised double-blind, placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilep Res 1990 Nov; 7: 136-45
11. Schapel GJ, Beran RG, Vajda FJE, et al. Double-blind, placebo-controlled crossover study of lamotrigine in treatment-resistant partial seizures. J Neurol Neurosurg Psychiatry 1993 May; 56: 448-53
12. Smith D, Baker G, Davies G. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993 Mar-Apr; 34: 312-22
13. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter placebo-controlled, double-blind, crossover trial. Epilepsia 1994 Jan-Feb; 35: 113-21
14. Binnie CD. The efficacy of lamotrigine. Rev Contemp Pharmacother 1994; 5: 115-22
15. Martin PJ, Miller PAH. Impact of lamotrigine on patients with refractory epilepsy: the Leicester experience. Seizure 1994; 3: 209-13
16. Timmings PL, Richens A. Lamotrigine in primary generalised epilepsy [letter]. Lancet 1992 May; 339: 1300-1
17. Vogt H, Lazareric G, Scalabrin JP, et al. Lamotrigine add-on therapy in 76 adult patients with refractory generalised epilepsies. Epilepsia 1994; 35 Suppl. 7: S71-2
18. Besag FMC, Wallace SJ, Dulac O, et al. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995; 127: 991-7
19. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995 Feb; 345: 476-9
20. Reunanen M, Dam M, Yuen AWC. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996 Mar; 23: 149-55
21. Steiner TJ, Silveira C, Yuen AWC. Comparison of lamotrigine (Lamictal) and phenytoin monotherapy in newly-diagnosed epilepsy [abstract]. Epilepsia 1994; 35 Suppl. 7: S61
22. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993 Jul; 46: 152-76
23. Schachter SC, Leppik IE, Matsuo F, et al. Lamotrigine: a six month, placebo-controlled, safety and tolerance study. J Epilepsy 1995; 8: 201-9
24. Marson AG, Kadir ZA, Hutton JL, et al. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38 Suppl. 8: 859-80
25. Mackay FJ, Wilton LV, Pearce GL, et al. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997; 38: 881-6
26. Tennis P, Stern RS. Risk of serious cutaneous disorders after the initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997; 49: 542-6
27. Steiner TJ, Findley LJ, Yuen AWC. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalagia 1997; 17: 109-12
28. Brodie MJ, Yuen AWC, and the 105 study group. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilep Res 1997; 26: 423-32